Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No

Daiichi Sankyo’s hope for a regulatory approval of its acute myeloid leukemia therapy quizartinib hit a snag after an advisory panel with the U.S. Food and Drug Administration (FDA) overwhelmingly voted against the medication due to safety concerns.